Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

653
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
653
Kidney Structure01:45

Kidney Structure

75.3K
The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
75.3K
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

728
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
728
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

932
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
932
Clinical Trials01:16

Clinical Trials

10.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  3. 研究分野
  5. 生物医学と臨床科学
  7. 腫瘍学とがん発生
  9. 分子標的
  11. 腎臓機能に対するランレオチドの作用: Dipak 1 ランダム化臨床試験

腎臓機能に対するランレオチドの作用: DIPAK 1 ランダム化臨床試験

Esther Meijer1, Folkert W Visser1,2, Rene M M van Aerts3

  • 1Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands.

JAMA
|November 14, 2018

関連する実験動画

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
10:51

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

Published on: December 2, 2014

11.5K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.0K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

PubMed で要約を見る

まとめ
この要約は機械生成です。

ランレオチドは,後期型自己支配性多囊性腎臓病 (ADPKD) の患者で2.5年以上にわたって腎臓機能の低下を遅らせなかった. この研究は,ランレオチドが進行したADPKDの治療に有効でないことを示唆しています.

科学分野:

  • 腎臓科
  • 臨床薬理学
  • 遺伝学

背景:

  • 自体主有多囊性腎臓病 (ADPKD) は,腎臓のキスタおよび機能喪失を引き起こす遺伝疾患であり,しばしば腎臓置換療法が必要である.
  • 後期段階のADPKDの管理には限られた治療法があり,効果的な治療法の必要性を強調しています.
  • ランレオチドのようなソマトスタチンの類型は,ADPKDの管理における潜在的な利点について調査されています.

研究 の 目的:

  • 遅い段階のADPKD患者の腎臓機能低下を遅らせることにランレオチドの有効性を評価する.
  • 腎機能の変化,腎臓の総体積,生活の質などの二次的なアウトカムに対するランレオチドの影響を評価する.

主な方法:

  • ADPKD (eGFR 30- 60 mL/ min/ 1. 73 m2) の後期的な患者309人を対象としたオープンなランダム化臨床試験.
  • 患者はランレオチドと標準治療,または標準治療のみを2.5年間受けた.
  • 主要評価項目は,推定グルメルフィルタレーション率 (eGFR) の年間減少率でした.

主要な成果:

  • ランレオチド治療は,標準治療と比較して,EGFRの年間減少率を有意に変化させなかった (- 3. 53 vs - 3. 46 mL/ min/ 1. 73 m2/ year).
  • 腎機能の悪化や生活の質の変化の有意な違いは認められなかった.

関連する実験動画

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
10:51

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys

Published on: December 2, 2014

11.5K
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.0K
Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K
  • ランレオチドは,腎臓の総体量の増加率 (年間5. 56%に対して4. 15%) が低下したが,胃腸の副作用は増加した.

    • 結論:

    • 遅い段階のADPKDの患者では,腎機能の低下を遅らせる効果は示されなかった.
    • 発見は,後期的なADPKDの治療にランレオチドの使用を支持しません.
    • ADPKDの代替治療戦略を探るにはさらなる研究が必要である.